Key result
Plasma MFAP4 is not prognostic of emphysema progression but is associated with cardiovascular disease history and mortality in COPD patients after smoking cessation.
Why the study?
COPD is associated with comorbidities like cardiovascular disease, but biomarkers to identify patients at risk of death and cardiovascular comorbidity remain needed.
Is plasma MFAP4 prognostic of emphysema progression, cardiovascular disease history, and mortality in COPD patients?
Observational
Is plasma MFAP4 prognostic of emphysema progression, cardiovascular disease history, and mortality in COPD patients?
Circulating MFAP4 may serve as a relevant biomarker to identify COPD patients at risk of death and cardiovascular comorbidity after smoking cessation.
MFAP4 may aid CVD and mortality risk stratification in COPD post-cessation; leaves open its prognostic value for emphysema progression.
Chronic obstructive pulmonary disease (COPD) is characterised by chronic airflow limitation and inflammation of the airways and lung parenchyma. COPD is associated with many comorbidities, especially cardiovascular disease (CVD), which share similar risk factors with COPD [1]. Circulating MFAP4 is a relevant biomarker to identify COPD patients at risk of death and cardiovascular comorbidity after smoking cessation
No takes yet. Share an insight, caveat, or question.
Johansson et al. (2019) conducted an observational in Chronic obstructive pulmonary disease (COPD). Plasma microfibrillar-associated protein 4 (MFAP4) was evaluated on Emphysema progression, cardiovascular disease history, and mortality. Plasma MFAP4 is not prognostic of emphysema progression but is associated with cardiovascular disease history and mortality in COPD patients after smoking cessation.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: